129 related articles for article (PubMed ID: 38752748)
41.
Duysburgh C; Van den Abbeele P; Morera M; Marzorati M
Benef Microbes; 2021 Aug; 12(4):59-73. PubMed ID: 34190033
[TBL] [Abstract][Full Text] [Related]
42. Joint protection strategies for Saccharomyces boulardii: exogenous encapsulation and endogenous biofilm structure.
Meng KL; Lv XC; Che HY; Li Y; Chen XL; Hu MX; Yan M
Appl Microbiol Biotechnol; 2021 Nov; 105(21-22):8469-8479. PubMed ID: 34647135
[TBL] [Abstract][Full Text] [Related]
43. Application of Saccharomyces cerevisiae var. boulardii in food processing: a review.
Lazo-Vélez MA; Serna-Saldívar SO; Rosales-Medina MF; Tinoco-Alvear M; Briones-García M
J Appl Microbiol; 2018 Oct; 125(4):943-951. PubMed ID: 29961970
[TBL] [Abstract][Full Text] [Related]
44. Effects of broad-spectrum antibiotics on the colonisation of probiotic yeast Saccharomyces boulardii in the murine gastrointestinal tract.
Hedin KA; Rees VE; Zhang H; Kruse V; Vazquez-Uribe R; Sommer MOA
Sci Rep; 2022 May; 12(1):8862. PubMed ID: 35614092
[TBL] [Abstract][Full Text] [Related]
45. Saccharomyces boulardii promoters for control of gene expression in vivo.
Sands C; Hedin KA; Vazquez-Uribe R; Sommer MOA
Microb Cell Fact; 2024 Jan; 23(1):16. PubMed ID: 38185666
[TBL] [Abstract][Full Text] [Related]
46. Molecular tools for differentiating probiotic and clinical strains of Saccharomyces cerevisiae.
Posteraro B; Sanguinetti M; Romano L; Torelli R; Novarese L; Fadda G
Int J Food Microbiol; 2005 Sep; 103(3):295-304. PubMed ID: 16099314
[TBL] [Abstract][Full Text] [Related]
47. The Probiotic Effects of the
Lee JE; Lee E
J Microbiol Biotechnol; 2022 Jul; 32(7):877-884. PubMed ID: 35791078
[TBL] [Abstract][Full Text] [Related]
48. Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition.
Rodríguez-Nogales A; Algieri F; Garrido-Mesa J; Vezza T; Utrilla MP; Chueca N; García F; Rodríguez-Cabezas ME; Gálvez J
J Nutr Biochem; 2018 Nov; 61():129-139. PubMed ID: 30236870
[TBL] [Abstract][Full Text] [Related]
49. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient.
Landaburu MF; López Daneri GA; Relloso S; Zarlenga LJ; Vinante MA; Mujica MT
Rev Argent Microbiol; 2020; 52(1):27-30. PubMed ID: 31262611
[TBL] [Abstract][Full Text] [Related]
50. [Saccharomyces boulardii CNCM I-745 influences the gut-associated immune system].
Stier H; Bischoff SC
MMW Fortschr Med; 2017 Jun; 159(Suppl 5):1-6. PubMed ID: 28643294
[TBL] [Abstract][Full Text] [Related]
51. Preventive Effect of
Babaei F; Mirzababaei M; Dargahi L; Shahsavari Z; Nassiri-Asl M; Karima S
ACS Chem Neurosci; 2022 Nov; 13(22):3180-3187. PubMed ID: 36318666
[TBL] [Abstract][Full Text] [Related]
52. Genetic basis for probiotic yeast phenotypes revealed by nanopore sequencing.
Collins JH; Kunyeit L; Weintraub S; Sharma N; White C; Haq N; Anu-Appaiah KA; Rao RP; Young EM
G3 (Bethesda); 2023 Aug; 13(8):. PubMed ID: 37103477
[TBL] [Abstract][Full Text] [Related]
53. Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice.
Hedin KA; Zhang H; Kruse V; Rees VE; Bäckhed F; Greiner TU; Vazquez-Uribe R; Sommer MOA
ACS Synth Biol; 2023 Nov; 12(11):3433-3442. PubMed ID: 37827516
[TBL] [Abstract][Full Text] [Related]
54. Development of a Novel ATP Bioluminescence Assay Based on Engineered Probiotic
Park JS; Kim YW; Kim H; Kim SK; Park K
J Microbiol Biotechnol; 2023 Nov; 33(11):1506-1512. PubMed ID: 37482802
[TBL] [Abstract][Full Text] [Related]
55. Heme Oxygenase-1 (
Imre A; Kovács R; Tóth Z; Majoros L; Benkő Z; Pfliegler WP; Pócsi I
J Fungi (Basel); 2022 May; 8(5):. PubMed ID: 35628777
[TBL] [Abstract][Full Text] [Related]
56. Saccharomyces boulardii Administration Changes Gut Microbiota and Attenuates D-Galactosamine-Induced Liver Injury.
Yu L; Zhao XK; Cheng ML; Yang GZ; Wang B; Liu HJ; Hu YX; Zhu LL; Zhang S; Xiao ZW; Liu YM; Zhang BF; Mu M
Sci Rep; 2017 May; 7(1):1359. PubMed ID: 28465509
[TBL] [Abstract][Full Text] [Related]
57. Improved Acetic Acid Resistance in Saccharomyces cerevisiae by Overexpression of the WHI2 Gene Identified through Inverse Metabolic Engineering.
Chen Y; Stabryla L; Wei N
Appl Environ Microbiol; 2016 Jan; 82(7):2156-2166. PubMed ID: 26826231
[TBL] [Abstract][Full Text] [Related]
58. Clinical Efficacy Comparison of Saccharomyces Boulardii and Lactic Acid as Probiotics in Acute Pediatric Diarrhea.
Asmat S; Shaukat F; Asmat R; Bakhat HFSG; Asmat TM
J Coll Physicians Surg Pak; 2018 Mar; 28(3):214-217. PubMed ID: 29544579
[TBL] [Abstract][Full Text] [Related]
59. Treatment of murine colitis by Saccharomyces boulardii secreting atrial natriuretic peptide.
Liu CH; Chang JH; Chang YC; Mou KY
J Mol Med (Berl); 2020 Dec; 98(12):1675-1687. PubMed ID: 33025105
[TBL] [Abstract][Full Text] [Related]
60. Influence of culture conditions on co-aggregation of probiotic yeast Saccharomyces boulardii with Candida spp. and their auto-aggregation.
Tomičić R; Tomičić Z; Raspor P
Folia Microbiol (Praha); 2022 Jun; 67(3):507-515. PubMed ID: 35169980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
